Interim Chief Executive Officer · C4 Therapeutics, Inc. (CCCC)

Marc Cohen

FY2020 is the first fiscal year CompBrief holds for Marc Cohen as a named executive officer of C4 Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$9,132,899

Salary $0Stock awards $0

2nd of 6 named executive officers at C4 Therapeutics by FY2020 total.

6 named officers on file for C4 Therapeutics, FY2020

Marc Cohen’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • CCCC’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how C4 Therapeutics’s whole pay program stands against its peers

  • C4 Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CCCC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2021 (DEF 14A).

Free

Get Marc Cohen’s full pay file as a PDF — free

More than this page: up to 10 years of Marc’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Marc Cohen compensation by year

C4 Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as C4 Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$0
Bonus$0
Stock awards$0
Option awards$9,063,399
Non-equity incentive$0
Pension and deferred compensation$0
All other$69,500
Total$9,132,899

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: C4 Therapeutics, Inc. DEF 14A filed April 26, 2021, accession 0001564590-21-020538, and prior-year filings. Open the filing on EDGAR.

How this page was built: the C4 Therapeutics, Inc. filed document, accession 0001564590-21-020538. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option3,210—$2.11
Option725,002—$19.00
Option17,786—$19.00

Per the Outstanding Equity Awards at Fiscal Year-End table in C4 Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

C4 Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Andrew HirschPresident & Chief Executive Officer$20,931,971
Marc Cohen · this pageInterim Chief Executive Officer$9,132,899
William McKeeFormer Chief Financial Officer$2,099,745
Adam CrystalChief Medical Officer$1,603,320
Stewart FisherChief Scientific Officer$1,589,693
Andrew PhillipsFormer President & Chief Executive Officer$618,275

Board service

C4 Therapeutics board · FY2021–FY2022
Director compensation in US dollars, as C4 Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2022$33,562—$103,595—$137,157
FY2021$82,972—$601,407—$684,379

Each year as the company reported it in C4 Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: C4 Therapeutics pays directors a $40,000 cash retainer. As stated in C4 Therapeutics's FY2025 proxy.

The full C4 Therapeutics compensation record

free company brief

This page is one person within C4 Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the C4 Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are C4 Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Marc Cohen's compensation dossier · One-time report. No refunds.